查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2030022

克隆和誘變市場－全球產業規模、佔有率、趨勢、機會和預測：按基因類型、產品類型、技術、應用、最終用戶、地區和競爭格局分類，2021-2031年

Cloning & Mutagenesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Gene Type, By Product Type, By Technique, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球克隆和誘變市場預計將從 2025 年的 31.1 億美元成長到 2031 年的 89.5 億美元，複合年成長率為 19.26%。

生物技術領域專注於人為改造遺傳物質，以創建生物體、細胞或DNA的完整副本（克隆），或進行靶向基因組修飾（誘變）。該領域的成長主要得益於基因工程的不斷進步、對個人化療法日益成長的需求，以及農業和工業應用領域基礎生物技術研究經費的增加。

市場概覽
預測期 2027-2031
市場規模：2025年 31.1億美元
市場規模：2031年 89.5億美元
複合年成長率：2026-2031年 19.26%
成長最快的細分市場 誘變試劑盒
最大的市場 北美洲

根據生物技術創新組織（BIO）的報告，預計到2024年，美國生物科學領域用於支持克隆和誘變技術的創業投資資金籌措將達到260億美元。儘管資金支持力度強勁，但由於基因工程領域複雜的監管和倫理框架，該市場仍面臨許多障礙。嚴格的監管和廣泛的社會支持對於這些技術的廣泛應用至關重要。

市場促進因素

全球克隆和誘變市場的主要驅動力是先進基因編輯工具的日益普及，這些工具顯著提高了基因修飾的精確度和速度。 CRISPR-Cas系統等突破性技術不斷提升基因組的精確修飾能力，從而促進了更具針對性的治療和研究。這些技術進步為科學家提供了強大的鹼基編輯、基因插入和基因敲除方法，加速了科學探索和實用化。鑑於這些基礎技術蘊含著巨大的經濟價值，Cure.指出，CRISPR Therapeutics宣布將於2026年3月將其可轉換債券發行規模擴大至5.5億美元。此舉將進一步推動基因編輯解決方案的創新和商業化。

同時，對個人化療法和個人化藥物日益成長的需求正對市場產生重大影響，因為這些療法和藥物需要根據每位患者的個別特徵進行精準的基因工程改造。克隆和誘變技術是開發這些個人治療方法的關鍵，在從治療細胞的構建到藥物測試疾病模型的建立等各個環節都發揮著至關重要的作用。這種策略使得醫療介入能夠根據個人的特定生活方式、環境因素和遺傳因素進行量身定做。這種需求的具體成果顯而易見。 2025年5月，個人化醫療聯盟向美國食品藥物管理局（FDA）報告稱，2024年已有18種新型個人化藥物和6種針對特定癌症和遺傳疾病的細胞及基因療法獲得核准。摩根大通的數據顯示，2026年第一季生物製藥授權協議總額達827億美元，反映了相關生物製藥產業的強勁發展動能。

市場挑戰

基因工程領域複雜的監管和倫理框架對全球克隆和誘變市場的擴張構成重大障礙。這種複雜性為創新者帶來了相當大的不確定性，導致產品開發週期延長，合規成本增加。此外，不同地區對監管規定的解讀差異以及嚴格的監管流程，會阻礙全球夥伴關係，延緩市場准入，最終阻礙新型基因工具的研發和商業性。

這一障礙直接影響新產品核准和市場准入的速度。例如，再生醫學聯盟預測，到2025年，美國僅有四到五種細胞和基因療法獲得核准。儘管基因工程領域取得了一系列科學突破，但如此低的上市數量凸顯了嚴格而漫長的監管程序如何限制了實驗室研究向商業化的轉化。因此，這種充滿挑戰的環境可能會阻礙關鍵資金籌措的流入，並減緩克隆和誘變技術產業關鍵應用的發展。

市場趨勢

實驗室操作的數位化和自動化正在透過提高數據可靠性和工作流程效率，改變全球克隆和誘變市場。雲端網路、先進軟體和機器人技術的整合，實現了精準且一致的複雜基因操作，最大限度地減少了人為錯誤，並提高了處理能力。這種轉變使實驗室能夠處理大規模的樣本和更複雜的實驗結構，而這些正是合成生物學和藥物發現的關鍵要素。賽默飛世爾科技在其2025年第四季財報電話會議（2026年1月29日）上重點強調了這一發展勢頭，並透露其生命科學解決方案部門（該部門提供實驗室工作流程設備）的銷售額成長了13%。

另一個重要趨勢是無縫、高通量克隆技術的進步。這項技術能夠快速且有效率地組裝重組DNA，無需傳統方法中繁瑣的步驟。這些改進使科學家能夠快速產生並同時測試多種表現型載體和基因變體，從而加速治療方法創新和研究的整體進程。透過減少技術延誤，這些最佳化的流程拓展了先進基因工程專案的可能性。為了佐證對這些高度擴充性的生物製造解決方案的需求，賽多利斯股份公司在其於2026年2月3日發布的2025年初步數據顯示，其生物製程解決方案部門的銷售額在不計外匯波動影響的情況下成長了9.5%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球複製與誘變市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依基因型（標準型、複雜型）
    • 產品類型（克隆試劑盒、突變試劑盒）
    • 依技術分類（拓樸PCR克隆、平端克隆、無縫克隆、特異性突變等）
    • 依應用領域（基因合成、基因表現、基因治療、疫苗研究等）
    • 按最終用戶（製藥和生物技術公司、學術和研究機構、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美克隆與誘變市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲克隆與誘變市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區克隆與誘變市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲克隆與誘變市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲克隆與誘變市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球克隆與誘變市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Agilent Technologies Inc.
  • Eurofins Scientific SE
  • Sartorius AG
  • Collecta Inc.
  • Codex DNA Inc.
  • Lonza Group AG
  • Charles River Laboratories International Inc.
  • TransGene Biotech Co. Ltd.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 14421

The Global Cloning and Mutagenesis Market is anticipated to expand from USD 3.11 billion in 2025 to USD 8.95 billion by 2031, reflecting a compound annual growth rate (CAGR) of 19.26%. This specialized biotechnology field centers on the intentional alteration of genetic material to either produce exact replicas of organisms, cells, or DNA (cloning) or to initiate targeted genomic modifications (mutagenesis). Growth in this sector is largely fueled by ongoing progress in genetic engineering, a rising need for personalized therapies, and increasing funding for basic biotech research spanning agricultural and industrial uses.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.11 Billion
Market Size 2031USD 8.95 Billion
CAGR 2026-203119.26%
Fastest Growing SegmentMutagenesis Kits
Largest MarketNorth America

Venture capital funding within the U.S. bioscience sector, which underpins cloning and mutagenesis technologies, achieved $26 billion in 2024, as reported by the Biotechnology Innovation Organization (BIO). Despite this strong financial backing, the market faces considerable obstacles due to the intricate regulatory and ethical frameworks surrounding genetic manipulation, which require strict supervision and widespread public approval to ensure broader adoption.

Market Driver

A major catalyst for the Global Cloning and Mutagenesis Market is the rising use of sophisticated gene editing tools, which greatly improve the accuracy and speed of genetic alterations. Breakthroughs like the CRISPR-Cas system consistently enhance the capacity for precise genomic modifications, facilitating more focused therapeutic and research initiatives. By equipping scientists with robust methods for base editing, gene insertion, and gene knockout, these technological strides expedite both scientific exploration and practical application. Reflecting the substantial financial interest in these foundational technologies, Cure. noted that CRISPR Therapeutics declared an upsized $550 million convertible senior notes offering in March 2026, a move that will further drive innovation and the commercialization of gene editing solutions.

At the same time, the escalating need for customized therapeutics and personalized medicine heavily impacts the market, as it demands precise genetic adjustments suited to unique patient characteristics. Methods in cloning and mutagenesis are essential for producing these individualized therapies, playing a role in everything from engineering therapeutic cells to establishing disease models for medication testing. This strategy tailors healthcare interventions to a person's specific lifestyle, environmental, and genetic elements. The tangible results of this demand are evident; the Personalized Medicine Coalition reported to the FDA in May 2025 that 2024 saw the approval of 18 novel personalized medicines and six cell- and gene-based treatments for specific cancers and genetic disorders. Highlighting the robust nature of the associated biopharma industry, JPMorgan recorded $82.7 billion in announced biopharma licensing values during the first quarter of 2026.

Market Challenge

The elaborate regulatory and ethical frameworks surrounding genetic manipulation pose a major hurdle for the expansion of the Global Cloning and Mutagenesis Market. This complicated setting introduces considerable unpredictability for innovators, resulting in extended product development schedules and higher expenses related to maintaining compliance. Furthermore, differing regulatory interpretations and strict supervisory processes across various regions can obstruct global partnerships and delay market access, ultimately impeding the progress and commercial rollout of novel genetic tools.

This obstacle directly affects how quickly new products are approved and introduced to the market. For example, the Alliance for Regenerative Medicine indicated that the United States was on track to approve merely 4 to 5 cell and gene therapies in 2025. Despite continuous scientific breakthroughs in genetic engineering, this low volume of market introductions highlights the extent to which strict and lengthy regulatory procedures restrict the shift from laboratory research to commercial availability. Consequently, such a demanding landscape may discourage essential funding, decelerating the growth of vital applications in the cloning and mutagenesis industry.

Market Trends

The digitization and automation of laboratory operations are profoundly transforming the Global Cloning and Mutagenesis Market by improving data reliability and workflow efficiency. Incorporating cloud networks, sophisticated software, and robotics enables the accurate and consistent performance of intricate genetic procedures, thereby minimizing human mistakes and boosting processing capacity. This shift allows laboratories to manage greater sample sizes and more complex experimental structures, both of which are vital for synthetic biology and pharmaceutical discovery. Thermo Fisher Scientific Inc. highlighted this momentum in its January 29, 2026, earnings call for the fourth quarter of 2025, revealing a 13% revenue growth in its Life Science Solutions division, which supplies laboratory workflow instruments.

Another crucial trend is the advancement of seamless, high-throughput cloning techniques, which facilitate the swift and effective assembly of recombinant DNA without the tedious phases of conventional methods. These improvements empower scientists to rapidly produce numerous expression vectors and gene variants for simultaneous testing, hastening the overall trajectory of therapeutic innovation and research. By reducing technical delays, these optimized processes broaden the potential for sophisticated genetic engineering endeavors. Highlighting the need for these scalable biomanufacturing solutions, Sartorius AG reported in its February 3, 2026, preliminary data for 2025 that its Bioprocess Solutions Division experienced a 9.5% rise in sales revenue in constant currencies.

Key Market Players

  • Agilent Technologies Inc.
  • Eurofins Scientific SE
  • Sartorius AG
  • Collecta Inc.
  • Codex DNA Inc.
  • Lonza Group AG
  • Charles River Laboratories International Inc.
  • TransGene Biotech Co. Ltd.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific Inc.

Report Scope

In this report, the Global Cloning & Mutagenesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cloning & Mutagenesis Market, By Gene Type

  • Standard
  • Complex

Cloning & Mutagenesis Market, By Product Type

  • Cloning Kits
  • Mutagenesis Kits

Cloning & Mutagenesis Market, By Technique

  • Topo PCR Cloning
  • Blunt End Cloning
  • Seamless Cloning
  • Site-Directed Mutagenesis
  • Others

Cloning & Mutagenesis Market, By Application

  • Gene Synthesis
  • Gene Expression
  • Gene Therapy
  • Vaccine Research
  • Others

Cloning & Mutagenesis Market, By End User

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutions
  • Others

Cloning & Mutagenesis Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cloning & Mutagenesis Market.

Available Customizations:

Global Cloning & Mutagenesis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cloning & Mutagenesis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Gene Type (Standard, Complex)
    • 5.2.2. By Product Type (Cloning Kits, Mutagenesis Kits)
    • 5.2.3. By Technique (Topo PCR Cloning, Blunt End Cloning, Seamless Cloning, Site-Directed Mutagenesis, Others)
    • 5.2.4. By Application (Gene Synthesis, Gene Expression, Gene Therapy, Vaccine Research, Others)
    • 5.2.5. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Cloning & Mutagenesis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Gene Type
    • 6.2.2. By Product Type
    • 6.2.3. By Technique
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cloning & Mutagenesis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Gene Type
        • 6.3.1.2.2. By Product Type
        • 6.3.1.2.3. By Technique
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Cloning & Mutagenesis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Gene Type
        • 6.3.2.2.2. By Product Type
        • 6.3.2.2.3. By Technique
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Cloning & Mutagenesis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Gene Type
        • 6.3.3.2.2. By Product Type
        • 6.3.3.2.3. By Technique
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Cloning & Mutagenesis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Gene Type
    • 7.2.2. By Product Type
    • 7.2.3. By Technique
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cloning & Mutagenesis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Gene Type
        • 7.3.1.2.2. By Product Type
        • 7.3.1.2.3. By Technique
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. France Cloning & Mutagenesis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Gene Type
        • 7.3.2.2.2. By Product Type
        • 7.3.2.2.3. By Technique
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Cloning & Mutagenesis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Gene Type
        • 7.3.3.2.2. By Product Type
        • 7.3.3.2.3. By Technique
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Cloning & Mutagenesis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Gene Type
        • 7.3.4.2.2. By Product Type
        • 7.3.4.2.3. By Technique
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Cloning & Mutagenesis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Gene Type
        • 7.3.5.2.2. By Product Type
        • 7.3.5.2.3. By Technique
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia Pacific Cloning & Mutagenesis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Gene Type
    • 8.2.2. By Product Type
    • 8.2.3. By Technique
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cloning & Mutagenesis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Gene Type
        • 8.3.1.2.2. By Product Type
        • 8.3.1.2.3. By Technique
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. India Cloning & Mutagenesis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Gene Type
        • 8.3.2.2.2. By Product Type
        • 8.3.2.2.3. By Technique
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Cloning & Mutagenesis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Gene Type
        • 8.3.3.2.2. By Product Type
        • 8.3.3.2.3. By Technique
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Cloning & Mutagenesis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Gene Type
        • 8.3.4.2.2. By Product Type
        • 8.3.4.2.3. By Technique
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Cloning & Mutagenesis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Gene Type
        • 8.3.5.2.2. By Product Type
        • 8.3.5.2.3. By Technique
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. Middle East & Africa Cloning & Mutagenesis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Gene Type
    • 9.2.2. By Product Type
    • 9.2.3. By Technique
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cloning & Mutagenesis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Gene Type
        • 9.3.1.2.2. By Product Type
        • 9.3.1.2.3. By Technique
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE Cloning & Mutagenesis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Gene Type
        • 9.3.2.2.2. By Product Type
        • 9.3.2.2.3. By Technique
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa Cloning & Mutagenesis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Gene Type
        • 9.3.3.2.2. By Product Type
        • 9.3.3.2.3. By Technique
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. South America Cloning & Mutagenesis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Gene Type
    • 10.2.2. By Product Type
    • 10.2.3. By Technique
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cloning & Mutagenesis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Gene Type
        • 10.3.1.2.2. By Product Type
        • 10.3.1.2.3. By Technique
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia Cloning & Mutagenesis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Gene Type
        • 10.3.2.2.2. By Product Type
        • 10.3.2.2.3. By Technique
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina Cloning & Mutagenesis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Gene Type
        • 10.3.3.2.2. By Product Type
        • 10.3.3.2.3. By Technique
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cloning & Mutagenesis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Agilent Technologies Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Eurofins Scientific SE
  • 15.3. Sartorius AG
  • 15.4. Collecta Inc.
  • 15.5. Codex DNA Inc.
  • 15.6. Lonza Group AG
  • 15.7. Charles River Laboratories International Inc.
  • 15.8. TransGene Biotech Co. Ltd.
  • 15.9. Takara Bio, Inc.
  • 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer